花旗发表研究报告，将再鼎医药(09688.HK) (ZLAB.US) 美股目标价从71美元下调至66美元，并相应调整了每股盈测，因采用再鼎医药2024年年末股数而非之前的2024年加权平均股数。今年下半年再鼎医药受到旗下药物Vyvgart、Xacduro、Augtyro和Nuzyra加速增长的支撑，花旗将其收入预测略微调整至指引的高端。花旗的预测与再鼎医药管理层先前沟通的目标一致，即在2025年第四季度实现非GAAP盈利。
该行予再鼎医药美股评级“买入/高风险”。该行相信再鼎医药的商业策略通过引进外国药物并在中国市场推进上市，能创造显著价值，其内部开发的产品管线也逐渐成为投资论点的重要驱动力(例如DLL3)。(hc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-06-10 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.